Lenz Oliver, Fornoni Alessia
Division of Nephrology and Hypertension, Department of Medicine, University of Miami Leonard Miller School of Medicine, Miami, Florida 33136, USA.
Kidney Int. 2008 Oct;74(7):851-3. doi: 10.1038/ki.2008.391.
Lee et al. report that an angiotensin II type 1 receptor blocker (ARB) improved glucose intolerance in OLETF rats, an experimental model of type 2 diabetes. ARB treatment resulted in modulation of the adipose tissue, leading to an increased number of small, differentiated adipocytes able to produce more adiponectin and less monocyte chemoattractant protein-1 and plasminogen activator inhibitor-1. This supports the relevance of the functional interplay between adipose tissue and the renin-angiotensin system in states of insulin resistance.
李等人报告称，血管紧张素II 1型受体阻滞剂（ARB）改善了OLETF大鼠（一种2型糖尿病实验模型）的葡萄糖不耐受情况。ARB治疗导致脂肪组织发生调节变化，使得能够产生更多脂联素、更少单核细胞趋化蛋白-1和纤溶酶原激活物抑制剂-1的小的、已分化脂肪细胞数量增加。这支持了在胰岛素抵抗状态下脂肪组织与肾素-血管紧张素系统之间功能相互作用的相关性。
